Kane Biotech (CVE:KNE) Trading Up 16.7% – Here’s What Happened

Kane Biotech Inc. (CVE:KNE)’s share price was up 16.7% on Thursday . The stock traded as high as C$0.04 and last traded at C$0.04. Approximately 249,090 shares changed hands during trading, an increase of 24% from the average daily volume of 201,259 shares. The stock had previously closed at C$0.03.

Kane Biotech Price Performance

The company has a debt-to-equity ratio of -308.66, a current ratio of 0.68 and a quick ratio of 0.39. The firm’s 50-day moving average price is C$0.03 and its 200 day moving average price is C$0.04. The firm has a market cap of C$6.36 million, a P/E ratio of -1.75 and a beta of 1.03.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.